Bayer's Dual Product Momentum Meets a Split Analyst Verdict and a Looming Roundup Ruling

Bayer has given investors two fresh operational markers in as many days — the first US shipment of its Convintro herbicide and FDA approval for its stroke drug Sunharbo — yet the market's response to the news has been anything but uniform, with two major brokers landing on opposite sides of the same set of facts.

The herbicide, which Bayer says is on track for availability in time for the 2027 corn season, represents the first tangible delivery step on the crop science side. The drug approval, granted for the active ingredient Asundexian and aimed at cutting the risk of recurrent stroke in adults who have suffered a non-cardioembolic ischemic stroke or a high-risk TIA, carries a different kind of weight: according to Bayer, it is the first approved Factor XIa inhibitor, and it is intended for use alongside antiplatelet therapy. Reuters attributed a temporary share price gain on the day to that regulatory win.

Where the two brokers diverge is on what all this is worth. Jefferies analyst Michael Leuchten called the approval expected and said it substantially reduces risk to Bayer's pharma pipeline — but the house kept its Hold rating and a €48.50 price target, well below the stock's €57.22 close. Deutsche Bank, by contrast, lifted its target from €60.00 to €65.00 and reaffirmed its Buy, citing higher earnings estimates following the third quarter.

The Numbers Behind the Split

The third-quarter release, published roughly a week ago, gives both camps something to work with. Bayer reported revenue of €10.053 billion and EBITDA before special items of €1.615 billion, and it raised its full-year outlook. Reuters reported that the company credited a better-than-expected performance in its pharmaceuticals division for the upgrade. For the full year 2026, Bayer now expects currency-adjusted EBITDA before special items of €9.8 billion to €10.3 billion.

Should investors sell immediately? Or is it worth buying Bayer?

That guidance matters because it sets the bar against which the product news will ultimately be judged. An approval and a shipment are operational milestones; whether they translate into earnings is a separate question, and it is the one that will decide whether the more bullish case holds. The Jefferies stance is a reminder that a meaningful reduction in pipeline risk does not automatically command a higher valuation — Leuchten acknowledges the drop in development risk and still stays on the sidelines.

Momentum Versus Expectations

Complicating the picture further is how much of the good news is already priced in. The stock has climbed 55% since the start of the year, a run that raises the cost of any disappointment. In the optimistic reading, the improved operational trajectory and the diminished development risk reinforce each other: if Bayer converts its regulatory wins into commercial results, the pharma division could keep justifying the raised annual outlook and lay the groundwork for further earnings gains. The less favorable scenario sees earnings improving more slowly than hopeful investors anticipate, widening the gap between business progress and market valuation — a strain that would be sharpest if the pharma unit were to offer weaker support for those higher profit expectations.

The next real test will be further operating results and management commentary on how the approvals are being commercialized. That is where the question of whether reduced development risk becomes a durable earnings base will be answered.

Roundup Still Casts a Shadow

Running alongside the product story is the unresolved legal question. Chief executive Bill Anderson said on November 4 that Bayer expects a court decision before Christmas on its proposed Roundup settlement, a $7.25 billion package under review by a court in Missouri, according to media reports. Until that review concludes, the legal overhang caps how positive the overall assessment can reasonably be. Anderson's timeline offers a reference point, but the ruling itself is the court's to make.

Taken together, the picture is cautiously constructive rather than decisively bullish. Convintro's first shipment, the Sunharbo approval and the raised guidance all argue in Bayer's favor — provided they convert into economic progress. A materially more robust investment case would need legal relief on top of that. Until the court rules, the operational strides deserve credit, with a clear caveat attached to the settlement still awaiting judgment.

Ad

Bayer Stock: New Analysis - 11 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...